Cyclophilin A-Nuclear factor kappa B-Matrix metalloproteinase-9 pathway (CypA-NF-κB-MMP-9 pathway)

The Cyclophilin A-Nuclear factor kappa B-Matrix metalloproteinase-9 pathway is a critical inflammatory signaling cascade that mediates extracellular matrix degradation, barrier dysfunction, and tissue destruction in multiple pathological conditions. This pathway begins when Cyclophilin A, a peptidyl-prolyl cis-trans isomerase that is abundantly expressed in inflammatory conditions, binds directly to its membrane receptor CD147 (also known as EMMPRIN - extracellular matrix metalloproteinase inducer) on the surface of monocytes, macrophages, and other immune cells[1][2]. Upon CypA-CD147 binding, the signal is transduced through the MAPK signaling cascades, specifically the ERK1/2 and JNK pathways, but not the p38 MAPK pathway[1][2]. These activated MAPK pathways then trigger the phosphorylation and degradation of inhibitor κB (IκB), liberating NF-κB dimers (predominantly p50/p65) which translocate to the nucleus[1]. Once in the nucleus, NF-κB binds to specific κB sites in the promoter region of the MMP-9 gene, dramatically upregulating MMP-9 transcription and subsequent protein expression[1][6]. The elevated MMP-9, a zinc-dependent endopeptidase, then degrades extracellular matrix components including tight junction proteins, leading to increased cellular invasion, tissue destruction, and barrier permeability[1][5]. This pathway has been extensively characterized in rheumatoid arthritis, where it contributes to cartilage and bone destruction, and in neurological conditions where it disrupts blood-brain barrier and blood-spinal cord barrier integrity[1][5]. The pathway is therapeutically targetable at multiple nodes: CypA can be inhibited by cyclosporine A, CD147 can be blocked by antagonistic peptides like AP-9, the MAPK cascades can be interrupted by specific kinase inhibitors, and NF-κB activation can be suppressed by various agents including statins, edaravone, and cilostazol[1][4][5]. Importantly, CypA stimulation specifically increases MMP-9 expression but not MMP-2, and this effect is more pronounced in differentiated macrophages compared to monocytes due to higher CD147 receptor expression on macrophages[1].

Other names

Cyclophilin A-NF-kappaB-MMP-9 pathwayCypA-NFκB-MMP-9 signaling pathwayCyclophilin A-Matrix metalloproteinase-9 pathwayCyPA-EMMPRIN-MMP-9 pathway (when CD147/EMMPRIN is emphasized)

CypA inhibition (cyclosporine A blocks CypA binding to CD147); CD147 receptor antagonism (AP-9 blocks membrane CD147); ERK/MAPK pathway inhibition (U0126 blocks ERK1/2-mediated NF-κB activation); JNK/MAPK pathway inhibition (SP600125 blocks JNK-mediated NF-κB activation); NF-κB transcriptional activity suppression (prevents nuclear translocation of p50/p65 dimers); MMP-9 transcriptional downregulation; IκB degradation prevention; ROS scavenging (indirect pathway inhibition)